Ventricular Arrhythmias in Uremic Cardiomyopathy

Understanding the Molecular Basis of Ventricular Arrhythmias in Uremic Cardiomyopathy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01856400

Enrollment

Registered

2013-05-17

Start date

2010-01-31

Completion date

2013-08-31

Last updated

2014-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy

Keywords

ventricular arrythmias, SERCA2a, Chronic Kidney Disease, microvolt T wave alternans

Brief summary

There is a certain gene called sarcoplasmic reticulum gene (SERCA2a), which is found in heart muscle. This gene is also found in blood vessels and skin tissue. When active this gene builds a crucial protein inside the heart muscle called SERCA2a protein. This is responsible for regulating calcium levels inside your heart muscle. When this gene is not activated, studies have shown that it can lead to abnormal electrical currents in the heart that can lead to death. The investigators are conducting this study to prove that SERCA2a gene is inactive in patients with kidney disease. Scientists found that patient at risk for abnormal electrical currents in the heart can be tested by what they called microvolt Twave alternans. This is a very delicate machine much more sensitive than a regular electrocardiogram that you do at the cardiology office.

Detailed description

This study will test the hypothesis that patients with uremic cardiomyopathy have reduced levels of SERCA2a protein compared to those with normal kidney function. We propose that such a correlation will provide convincing evidence that these patients,have a defective redistribution in intracellular calcium handling as an explanation for their increase risk in sudden cardiac death an fatal arrhythmias. To achieve our specific aims: 1) we will screen patients with end stage renal disease (ESRD) going for certain vascular procedures. 2) obtain an echocardiogram on these patients including only those with isolated diastolic dysfunction or LVH. 3) Patients who has diastolic dysfunction or LVH will be assessed for underlying microvolt (TWA) 4) vessel and skin tissue on these patients will be collected for SERCA2a quantification.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* age 18 years or older * Patients with stage 5 CKD or ESRD and those with normal CKD will be considered as possible candidates if admitted for one of the following vascular procedures * coronary artery bypass grafting, or vascular bypass surgery, or arteriovenous fistula creation, or arteriovenous graft surgery. * The aforementioned patients will be included if they have LVH or diastolic dysfunction and a normal LVEF on echocardiogram within one year of their scheduled surgery.

Exclusion criteria

1. Age less than 18 ; 2. Pregnancy; 3. Dilated cardiomyopathy; 4. left ventricular ejection fraction (LVEF) less than or equal to 50%; 5. Patients on digoxin. 6. antiarrhytmic medications; 7. baseline electrolyte abnormalities; 8. Atrial fibrillation; 9. Bundle branch block

Design outcomes

Primary

Measure	Time frame	Description
Molecular basis of ventricular arrythmias in uremic cardiomyopathy	At time of surgery	To assess the expression of SERCA2a gene expression in Uremic Cardiomyopathy patients to see if the degree of expression is implicated in ventricular arrythmias

Countries

United States

Outcome results